STX

SHIELD THERAPEUTICS PLC ORD 1.5P

TitleTime
2019 Annual Report and 2020 AGM NoticeFri 22/05/20 | 16:15
Second Price Monitoring ExtnThu 21/05/20 | 16:40
Price Monitoring ExtensionThu 21/05/20 | 16:35
Preliminary ResultsThu 21/05/20 | 07:00
Notice of ResultsTue 19/05/20 | 07:00
Business and trading updateFri 01/05/20 | 07:00
Total Voting Rights UpdateThu 30/04/20 | 17:23
Further re. Directorate ChangeMon 27/04/20 | 07:00
Directorate ChangeWed 22/04/20 | 07:00
Second Price Monitoring ExtnThu 26/03/20 | 16:42
Price Monitoring ExtensionThu 26/03/20 | 16:36
Holding(s) in CompanyFri 20/03/20 | 11:36
Second Price Monitoring ExtnTue 17/03/20 | 14:06
Price Monitoring ExtensionTue 17/03/20 | 14:00
AEGIS-H2H study updateTue 17/03/20 | 07:00
Block Listing ApplicationMon 02/03/20 | 16:41
Holding(s) in CompanyFri 21/02/20 | 11:14
Business and trading updateMon 27/01/20 | 07:00
China licence agreement for Feraccru/AccruferWed 08/01/20 | 07:00
Eland Oil & GasThu 12/12/19 | 17:30
Holding(s) in CompanyFri 29/11/19 | 15:31
QCA Corporate Governance CodeMon 25/11/19 | 07:00
Positive results presented at UEG Week 2019Tue 22/10/19 | 07:00
Director/PDMR ShareholdingThu 15/08/19 | 10:17
Half-year ReportWed 07/08/19 | 07:00
Notice of ResultsWed 31/07/19 | 13:21
Second Price Monitoring ExtnFri 26/07/19 | 14:05
Price Monitoring ExtensionFri 26/07/19 | 14:00
FDA approves Feraccru® with a broad labelFri 26/07/19 | 07:00
Additional ListingTue 02/07/19 | 12:00
Result of AGMThu 13/06/19 | 14:16
Update on Legal ProceedingsMon 03/06/19 | 07:00
Appointment of Joint BrokerWed 08/05/19 | 07:00
Additional ListingWed 01/05/19 | 11:58
2018 Annual Report and 2019 AGM NoticeTue 30/04/19 | 07:00
PDMR Acquisition of SharesFri 26/04/19 | 18:05
Major extension to approval in SwitzerlandWed 24/04/19 | 07:00
Grant of share optionsWed 17/04/19 | 17:06
PDMR Acquisition of Shares and Additional ListingWed 17/04/19 | 17:01
PDMR Acquisition of SharesWed 17/04/19 | 16:56
Holding(s) in CompanyThu 11/04/19 | 16:40
Additional ListingMon 08/04/19 | 15:42
Final ResultsWed 03/04/19 | 07:00
Additional ListingMon 01/04/19 | 17:44
Change of AdviserMon 01/04/19 | 12:00
Notice of ResultsWed 27/03/19 | 07:00
Positive decision on Feraccru®'s process patentThu 14/03/19 | 15:31
Positive results for Feraccru® in AEGIS-H2H studyMon 04/03/19 | 07:00
Positive results of AEGIS-CKD studyTue 29/01/19 | 07:00
Business and trading updateThu 24/01/19 | 07:00
Appointment of ChairmanTue 22/01/19 | 07:00
US New Drug Application PDUFA date for FeraccruThu 13/12/18 | 07:00
New Drug Application for Feraccru®Mon 03/12/18 | 07:00
Holding(s) in CompanyFri 09/11/18 | 15:46
Holding(s) in CompanyThu 08/11/18 | 18:21
Notification Of Major HoldingsMon 01/10/18 | 13:54
Submission of an NDA for Feraccru® with the FDAMon 01/10/18 | 07:00
Director/PDMR ShareholdingMon 24/09/18 | 13:06
Holding(s) in CompanyMon 24/09/18 | 13:02
Licence for the commercialisation of FeraccruWed 19/09/18 | 07:14
Interim ResultsWed 19/09/18 | 07:12
AEGIS-H2H Completion of RecruitmentThu 13/09/18 | 07:00
Appointment of Non-Executive DirectorThu 26/07/18 | 07:00
Business UpdateMon 23/07/18 | 07:00
Holdings in CompanyMon 09/07/18 | 16:27
Holdings in CompanyMon 09/07/18 | 16:26
Result of AGMThu 28/06/18 | 11:56
Positive top-line results from AEGIS-PAED PK studyThu 14/06/18 | 07:00
Directorate ChangeTue 05/06/18 | 07:00
2017 Annual Report and 2018 AGM NoticeTue 05/06/18 | 07:00
Grant of share optionsTue 15/05/18 | 18:21
Holding(s) in CompanyFri 04/05/18 | 09:20
Holding(s) in CompanyThu 03/05/18 | 17:26
Price Monitoring ExtensionWed 02/05/18 | 11:00
Preliminary Results for the Year Ended 31 Dec 17Wed 11/04/18 | 07:00
Appointment of Non-Executive DirectorFri 06/04/18 | 07:00
Results of Pre-Submission Meeting with FDAFri 06/04/18 | 07:00
Broadening of Feraccru indicationTue 27/03/18 | 07:00
Update on the AEGIS-CKD studyFri 16/03/18 | 07:00
Receives CHMP positive opinion on Feraccru®Fri 23/02/18 | 13:56
Business and Trading UpdateThu 22/02/18 | 07:00
Top-line results from Feraccru Phase III studyMon 05/02/18 | 07:00
Notice of ResultsMon 29/01/18 | 07:00
Grant of share optionsThu 25/01/18 | 07:00
Completion of patient enrolment in Phase 3 studyTue 10/10/17 | 07:00
PDMR Acquisition of SharesThu 05/10/17 | 07:00
Interim ReportWed 20/09/17 | 07:00
Board ChangeThu 14/09/17 | 07:00
US Composition of Matter Patent AllowedWed 06/09/17 | 07:00
Shield to Present at Baird Healthcare ConferenceThu 31/08/17 | 07:00
Notice of ResultsTue 15/08/17 | 07:00
Grant of Share OptionsTue 11/07/17 | 14:59
Holding(s) in CompanyMon 10/07/17 | 16:16
Feraccru licence agreement for SwitzerlandThu 06/07/17 | 07:00
Holding(s) in CompanyWed 05/07/17 | 12:38
Warrant Exercise and ExpiryMon 03/07/17 | 12:34
Holding(s) in CompanyWed 28/06/17 | 10:37
Admission of New Ordinary SharesWed 28/06/17 | 08:00
Results of FundraiseThu 15/06/17 | 13:59
Proposed FundraiseThu 15/06/17 | 07:00